A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies Kohrt, H., Godwin, J. E., Lossos, I. S., Williams, M. E., Timmerman, J., Link, B. K., Goldberg, S. M., McGirr, A., Kurland, J. F., Wigginton, J. M., Cohen, L. J., Levy, R. AMER SOC CLINICAL ONCOLOGY. 2013

View details for Web of Science ID 000335419605402